Amalgamated Financial’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Amalgamated Financial’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$232K	Buy	+6,633	New	+$194K	﹤0.01%	1846

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Amalgamated Financial's CERE Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2022: 6,633 shares worth $232K. The stake represents ﹤0.01% of the portfolio and ranks #1846 among its holdings.

107 funds tracked by Wall St. Rank hold CERE as of Q1 2022.

Amalgamated Financial held 6,633 shares of Cerevel Therapeutics Holdings, Inc. Common Stock worth $232K as of Q1 2022.
Cerevel Therapeutics Holdings, Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
Cerevel Therapeutics Holdings, Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1846 holding.
107 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.